Wednesday, July 8, 2026

pharma · Cystic Fibrosis · Multiple Sclerosis · RARE

Ultragenyx UK

UGenDx is a pharma organization headquartered in NOVATO, CA, GB. It trades on NYSE under ticker RARE. Primary therapeutic focus areas include Cystic Fibrosis, Multiple Sclerosis, Fanconi's Anemia, Hereditary Inclusion Bo

Newcastle upon tyne, NE128RL, GB, NOVATO, CA HQ
2024 Founded
2 Employees
Public company Type
RARE · NYSE Ticker
Company details
Status
Public
HQ
Newcastle upon tyne, NE128RL, GB, NOVATO, CA
Founded
2024
Employees
2
Programs
201
Drugs
168
Patents
23
Clinical program

Rifampicin

Phase 3 · small molecule · Multiple System Atrophy

Rifampicin for Multiple System Atrophy is a Phase 3 program (small_molecule) at Ultragenyx UK Limited with 1 ClinicalTrials.gov record(s).

← All Ultragenyx UK Limited projects Phase 3 small molecule terminated

Internal code 10-003108

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Ultragenyx UK Limited
Phase
Phase 3
Modality
small_molecule
Indication
Multiple System Atrophy
Status
terminated
Trials
1